Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1560-1568

  Matayoshi, Sen ^a   Chiba, Shunmei ^a   Lin, Yanfui ^a   Arakaki, Kazunari ^a   Matsumoto, Hirofumi ^a   Nakanishi, Takaya ^a   Suzuki, Mikio ^a   Kato, Seiya ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Adenovirus vector; Head and neck squamous cell carcinoma; Lysophosphatidic acid receptor 4; Rac; Rho

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; CELL STIMULATION; DOWN REGULATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

AMIDES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; PYRIDINES; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION;

EID: 84875998108     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1849     Document Type: Article

References (42)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet 371: 1695-1709, 2008. (Pubitemid 351671886)
3. Matta A and Ralhan R: Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 1: 6, 2009.
4. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA and Grandis JR: The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160, 2011.
5. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V and Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45: 324-334, 2009.
6. Gendaszewska-Darmach E: Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases. Acta Biochim Pol 55: 227-240, 2008. (Pubitemid 351947537)
7. Mills GB and Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591, 2003. (Pubitemid 37328830)
8. Moolenaar WH: Lysophospholipids in the limelight: autotaxin takes center stage. J Cell Biol 158: 197-199, 2002.
9. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J and Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227-233, 2002.
10. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J and Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281: 25822-25830, 2006. (Pubitemid 44401970)
11. Yanagida K and Ishii S: Non-Edg family LPA receptors: the cutting edge of LPA research. J Biochem 150: 223-232, 2011.
12. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN and Chun J: LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186, 2010.
13. Meyer Zu Heringdorf D and Jakobs KH: Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 1768: 923-940, 2007. (Pubitemid 46452543)
14. Noguchi K, Ishii S and Shimizu T: Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278: 25600-25606, 2003. (Pubitemid 36835313)
15. Lee CW, Rivera R, Dubin AE and Chun J: LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem 282: 4310-4317, 2007. (Pubitemid 47100980)
16. Yanagida K, Ishii S, Hamano F, Noguchi K and Shimizu T: LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J Biol Chem 282: 5814-5824, 2007. (Pubitemid 47093762)
17. Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, Windle JJ, Chen CK and Fang X: Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 19: 5435-5445, 2008.
18. Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA and Billiard J: LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem 109: 794-800, 2010.
19. Gschwind A, Prenzel N and Ullrich A: Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 62: 6329-6336, 2002. (Pubitemid 35244489)
20. Suzuki Y, Ozawa Y, Murakami K and Miyazaki H: Lysophosphatidic acid inhibits epidermal-growth-factor-induced Stat1 signaling in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 240: 856-861, 1997. (Pubitemid 28271810)
21. Rolin J and Maghazachi AA: Effects of lysophospholipids on tumor microenvironment. Cancer Microenviron 4: 393-403, 2011.
22. Toyozumi Y, Arima N, Izumaru S, Kato S, Morimatsu M and Nakashima T: Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells. Int J Oncol 25: 721-728, 2004.
23. Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J and Ervin TJ: Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci USA 83: 2684-2688, 1986. (Pubitemid 16026948)
24. Msaki A, Sánchez AM, Koh LF, Barré B, Rocha S, Perkins ND and Johnson RF: The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival and migration. Mol Biol Cell 22: 3032-3040, 2011.
25. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M and Narumiya S: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994, 1997. (Pubitemid 27485693)
26. Lee CW, Rivera R, Gardell S, Dubin AE and Chun J: GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281: 23589-23597, 2006. (Pubitemid 44274133)
27. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, Taguchi R, Shimizu T and Ishii S: Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 284: 17731-17741, 2009.
28. Bhave SL, Teknos TN and Pan Q: Molecular parameters of head and neck cancer metastasis. Crit Rev Eukaryot Gene Expr 21: 143-153, 2011.
29. Hall A: Rho GTPases and the control of cell behaviour. Biochem Soc Trans 33: 891-895, 2005. (Pubitemid 41659073)
30. Routhier A, Astuccio M, Lahey D, Monfredo N, Johnson A, Callahan W, Partington A, Fellows K, Ouellette L, Zhidro S, Goodrow C, Smith A, Sullivan K, Simone P, Le L, Vezuli B, Zohni M, West E, Gleason D and Bryan B: Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep 23: 861-867, 2010.
31. Moore KA, Sethi R, Doanes AM, Johnson TM, Pracyk JB, Kirby M, Irani K, Goldschmidt-Clermont PJ and Finkel T: Rac1 is required for cell proliferation and G2/M progression. Biochem J 326: 17-20, 1997. (Pubitemid 27386912)
32. Mack NA, Whalley HJ, Castillo-Lluva S and Malliri A: The diverse roles of Rac signaling in tumorigenesis. Cell Cycle 10: 1571-1581, 2011.
33. Shoval I and Kalcheim C: Antagonistic activities of Rho and Rac GTPases underlie the transition from neural crest delamination to migration. Dev Dyn 241: 1155-1168, 2012.
34. Guilluy C, Garcia-Mata R and Burridge K: Rho protein crosstalk: another social network? Trends Cell Biol 21: 718-726, 2011.
35. Kramer RH, Shen X and Zhou H: Tumor cell invasion and survival in head and neck cancer. Cancer Metastasis Rev 24: 35-45, 2005. (Pubitemid 40576062)
36. Abraham MT, Kuriakose MA, Sacks PG, Yee H, Chiriboga L, Bearer EL and Delacure MD: Motility-related proteins as markers for head and neck squamous cell cancer. Laryngoscope 111: 1285-1289, 2001. (Pubitemid 32625422)
37. Abe M, Sogabe Y, Syuto T, Yokoyama Y and Ishikawa O: Evidence that PI3K, Rac, Rho and Rho kinase are involved in basic fibroblast growth factor-stimulated fibroblast-collagen matrix contraction. J Cell Biochem 102: 1290-1299, 2007. (Pubitemid 350220049)
38. Harper K, Arsenault D, Boulay-Jean S, Lauzier A, Lucien F and Dubois CM: Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Res 70: 4634-4643, 2010.
39. Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR, Marathe GK, McIntyre TM, Xu Y, Prestwich GD, Byun HS, Bittman R and Tigyi G: Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med 199: 763-774, 2004. (Pubitemid 38375196)
40. Liliom K, Tsukahara T, Tsukahara R, Zelman-Femiak M, Swiezewska and Tigyi G: Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs. Biochim Biophys Acta 1761: 1506-1514, 2006. (Pubitemid 44821912)
41. Tsukahara T: The role of PPARγ in the transcriptional control by agonists and antagonists. PPAR Res 2012: 362361, 2012.
42. Rodway HA, Hunt AN, Kohler JA, Postle AD and Lillycrop KA: Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor gamma activation induced by 15-deoxyDelta12,14- prostaglandin J2 in neuroblastoma cells. Biochem J 382: 83-91, 2004. (Pubitemid 39141569)